STTK Earnings
Tuesday, May 05 2026
EPS Estimate
$-0.13
$-0.17 – $-0.11
Current Price
$6.99
Our Position
bullish · highCantor Fitzgerald starts STTK Overweight
structured data
Strong insider buying and upgraded coverage indicate high conviction in the company's pipeline and growth potential, signaling confidence in future share price appreciation.
Watch: Watch FDA trial readouts on DR3 and TL1A programs as catalysts for valuation re-rating.
Data Signal Summary
1 bullish
1 bearish
Insider buying cluster
Price downtrend
Key Context
Insider Activity
buying
Price Trend
downtrend
1-Month Return
+11.8%
From 52w High
-11.3%
Est. Revisions (30d)
+1.5% 1up/0dn
Analyst Target (mean)
$12 $7–$18 +72%
Est. Dispersion
46% 5 analysts
Insider Cluster
strong buy (officer)
Fund Convergence
strong Renaissance, Two Sigma, Citadel
Recent Activity
insider trades
13 transactions
Award
·
SCHREIBER TAYLOR M.D., PH.D. (Chief Executive Officer)
·25,610 shares
·$22,222
Buy
·
ORBIMED ADVISORS, L.L.C. (Unknown)
·6,306,127 shares
·$5,471,826
Buy
·
ASHIYA MONA (Director)
·6,306,127 shares
·$5,471,826
Award
·
NEILL ANDREW R. (Chief Financial Officer)
·64,027 shares
·$55,556
Award
·
SHUKLA ABHINAV A. PH.D. (Chief Technology Officer)
·5,122 shares
·$4,444
8 more
Award
·
STOUT STEPHEN
·12,805 shr
·$11,111
Award
·
SIEGALL CLAY B
·128,054 shr
·$111,112
Buy
·
REDMILE GROUP, L.L.C.
·133,371 shr
·$166,714
Sell
·
REDMILE GROUP, L.L.C.
·133,371 shr
·$166,714
Buy
·
SCHREIBER TAYLOR M.D., PH.D.
·36,500 shr
·$44,220
Buy
·
BROUS TYLER
·8,416 shr
·$32,768
Buy
·
SCHREIBER TAYLOR M.D., PH.D.
·14,400 shr
·$50,011
Exercise
·
SCHREIBER TAYLOR M.D., PH.D.
·3,050 shr
·$10,888
Explore more
